Shares of Exelixis (NASDAQ: EXEL) are down 10% at 1:15 p.m. EDT following the release of third-quarter earnings yesterday after the bell.
Product revenue, which mostly comes from sales of Exelixis' liver and kidney cancer drug Cabometyx, came in at $191.8 million, a 17.7% year-over-year increase. While that's certainly solid growth on a yearly basis, it's down slightly from the $193.7 million in product sales Exelixis registered in the second quarter. And when you factor in a price increase, Cabometyx demand was down 4% quarter over quarter.
Image source: Getty Images.